[Treating juvenile nephrotic syndrome with levamisol: regarding a marketing suspension].
Manrique-Rodríguez
S
S
Martínez-Fernández-Llamazares
C
C
Sanjurjo-Sáez
M
M
D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D056736:Drug Recalls; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D007978:Levamisole / Q000600:supply & distribution* / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D056687:Off-Label Use; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction
D006852:Hydrochlorothiazide; D007978:Levamisole; D003520:Cyclophosphamide; D011241:Prednisone